ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

Fasenra generated $1.55bn last year, according to AstraZeneca’s financials. Image credit: Alexanderstock23 / Shutterstock. AstraZeneca‘s Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in

Four boys with a rare and of­ten se­vere ge­net­ic mus­cle dis­ease died in 2020 and 2021 af­ter re­ceiv­ing a one-time gene ther­a­py from Astel­las Phar­ma,

Methylone (TSND-201) is a rapid-acting neuroplastogen (a biological substrate not a therapeutic). Image Credit: MargJohnsonVA / Shutterstock. The US Department of Defense has awarded a